Dasatinib is an ATP-competitive, dual Src/Bcr-Abl kinase inhibitor that has recently entered the clinic for the treatment of chronic myelogenous leukaemia (CML) (Shah et al., 2004). The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.